CAR-NK and CAR-T cells for cancer with liver spread
Part of Cancer clinical trials.
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced cancer (like colorectal cancer) that has spread to the liver and standard treatments have stopped working
- You are generally healthy enough to be up and about (ECOG score 0-1)
- Your blood counts, kidney and liver function are within certain safe ranges
- You are willing to use effective birth control during and for 6 months after treatment (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
This Phase 1 trial tests the safety and early signs of effectiveness of an “armored” CAR-T cell therapy (C-CAR031) for advanced hepatocellular carcinoma (liver cancer). It may help by teaching the body’s immune cells to better recognize and attack the cancer.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Hear when a new Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.